Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities (2021 - 2025)

ARS Pharmaceuticals' Total Non-Current Liabilities history spans 4 years, with the latest figure at $208.8 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 121.28% year-over-year to $208.8 million; the TTM value through Dec 2025 reached $208.8 million, up 121.28%, while the annual FY2025 figure was $208.8 million, 121.28% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $208.8 million at ARS Pharmaceuticals, down from $221.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $221.4 million in Q3 2025 and bottomed at $8.5 million in Q4 2022.
  • The 4-year median for Total Non-Current Liabilities is $107.0 million (2024), against an average of $111.6 million.
  • The largest annual shift saw Total Non-Current Liabilities crashed 48.48% in 2022 before it soared 121.28% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $16.6 million in 2021, then plummeted by 48.48% to $8.5 million in 2022, then soared by 1003.7% to $94.4 million in 2024, then soared by 121.28% to $208.8 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Total Non-Current Liabilities are $208.8 million (Q4 2025), $221.4 million (Q3 2025), and $119.7 million (Q2 2025).